RESUMEN
BACKGROUND: CD6 is a lymphocyte surface co-receptor physically associated with the T-cell receptor (TCR)/CD3 complex at the center of the immunological synapse. There, CD6 assists in cell-to-cell contact stabilization and modulation of activation/differentiation events through interaction with CD166/ALCAM (activated leukocyte cell adhesion molecule), its main reported ligand. While accumulating evidence is attracting new interest on targeting CD6 for therapeutic purposes in autoimmune disorders, little is known on its potential in cancer. In an attempt to elucidate the in vivo relevance of blocking CD6-mediated interactions in health and disease, we explored the consequences of expressing high circulating levels of a soluble form CD6 (sCD6) as a decoy receptor. METHODS: High sCD6 serum levels were achieved by using transgenic C57BL/6 mice expressing human sCD6 under the control of lymphoid-specific transcriptional elements (shCD6LckEµTg) or wild type either transduced with hepatotropic adeno-associated virus coding for mouse sCD6 or undergoing repeated infusions of recombinant human sCD6 protein. Characterization of sCD6-induced changes was performed by ex vivo flow cytometry and functional analyses of mouse lymphoid organ cells. The in vivo relevance of those changes was explored by challenging mice with subcutaneous or metastatic tumors induced by syngeneic cancer cells of different lineage origins. RESULTS: Through a combination of in vitro and in vivo studies, we show that circulating sCD6 expression induces defective regulatory T cell (Treg) generation and function, decreased CD166/ALCAM-mediated tumor cell proliferation/migration and impaired galectin-induced T-cell apoptosis, supporting the fact that sCD6 modulates antitumor lymphocyte effector function and tumorigenesis. Accordingly, sCD6 expression in vivo resulted in delayed subcutaneous tumor growth and/or reduced metastasis on challenge of mice with syngeneic cancer cells. CONCLUSIONS: Evidence is provided for the disruption of CD6 receptor-ligand interactions as a feasible immunomodulatory approach in cancer.
Asunto(s)
Antígenos CD/sangre , Antígenos de Diferenciación de Linfocitos T/sangre , Neoplasias Pulmonares/inmunología , Linfoma de Células T/inmunología , Melanoma Experimental/inmunología , Sarcoma Experimental/inmunología , Linfocitos T Reguladores/inmunología , Molécula de Adhesión Celular del Leucocito Activado/inmunología , Molécula de Adhesión Celular del Leucocito Activado/metabolismo , Animales , Antígenos CD/administración & dosificación , Antígenos CD/biosíntesis , Antígenos CD/genética , Antígenos de Diferenciación de Linfocitos T/administración & dosificación , Antígenos de Diferenciación de Linfocitos T/biosíntesis , Antígenos de Diferenciación de Linfocitos T/genética , Apoptosis/fisiología , Diferenciación Celular/fisiología , Línea Celular Tumoral , Femenino , Humanos , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/secundario , Linfoma de Células T/metabolismo , Masculino , Melanoma Experimental/sangre , Melanoma Experimental/patología , Melanoma Experimental/terapia , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/sangre , Proteínas Recombinantes/genética , Sarcoma Experimental/sangre , Sarcoma Experimental/patología , Linfocitos T Reguladores/metabolismoRESUMEN
The lack of useful biomarkers is a crucial problem for patients with soft tissue sarcomas (STSs). Emerging evidence has suggested that circulating microRNAs (miRNAs) in body fluids have novel impact as biomarkers for patients with malignant diseases, but their significance in synovial sarcoma (SS) patients remains unknown. Initial global miRNA screening using SS patient serum and SS cell culture media identified a signature of four upregulated miRNAs. Among these candidates, miR-92b-3p secretion from SS cells was confirmed, which was embedded within tumour-derived exosomes rather than argonaute-2. Animal experiments revealed a close correlation between serum miR-92b-3p levels and tumour dynamics. Clinical relevance was validated in two independent clinical cohorts, and we subsequently identified that serum miR-92b-3p levels were significantly higher in SS patients in comparison to that in healthy individuals. Moreover, serum miR-92b-3p was robust in discriminating patients with SS from the other STS patients and reflected tumour burden in SS patients. Overall, liquid biopsy using serum miR-92b-3p expression levels may represent a novel approach for monitoring tumour dynamics of SS.
Asunto(s)
Biomarcadores de Tumor/sangre , MicroARN Circulante/genética , MicroARNs/genética , Sarcoma Experimental/diagnóstico , Sarcoma Sinovial/diagnóstico , Sarcoma/diagnóstico , Adulto , Animales , Estudios de Casos y Controles , Niño , MicroARN Circulante/sangre , Diagnóstico Diferencial , Exosomas/metabolismo , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Masculino , Ratones Endogámicos BALB C , Ratones Desnudos , MicroARNs/sangre , Persona de Mediana Edad , Sarcoma/sangre , Sarcoma/genética , Sarcoma Experimental/sangre , Sarcoma Experimental/genética , Sarcoma Sinovial/sangre , Sarcoma Sinovial/genética , Células Tumorales Cultivadas , Adulto JovenRESUMEN
Tumor models are essential for basic anticancer research and development of novel therapies. In this study, we used a rat sarcoma model in which subcutaneous tumor develops after D6 cell inoculation. The aim of the current study was to analyze changes in haematological parameters, immune cell sub-populations and cytokine profiling during tumor growth, after tumor excision and after second inoculation of D6 cells. Tumor progression was found to be associated with an increased number of leukocytes and increased proportion of CD11b+ cells in peripheral blood. Serum concentration of chemokine (c-c motif) ligand 2, L-selectin and intra cellular adhesion molecule-1 also increased with growing tumor. However, the proportion of CD4+, CD8+ and MHC II+ cells decreased with growth of tumors. After tumor excision, all these parameters returned to pre-inoculation levels and did not change even after a second inoculation of D6 cells. Moreover, absence of secondary tumors after second inoculation of D6 cells gives an insight into development of antitumor immunity stimulated by primary tumor.
Asunto(s)
Antígeno CD11b/sangre , Quimiocina CCL2/sangre , Sarcoma Experimental/patología , Animales , Progresión de la Enfermedad , Citometría de Flujo , Leucocitosis , Ratas , Ratas Endogámicas Lew , Sarcoma Experimental/sangreRESUMEN
Blood cell counts, differential blood cell counts and weights of the spleen and peripheral lymph nodes draining the area of lesions induced by Moloney sarcoma virus inoculation into the quadriceps shank muscles of inbred BALB/c mice were examined at various stages of tumor development and regression. The blood cell count remained constant through the observation period up to 27 days post tumor development and regression. Differential counts revealed some changes in the cellular composition of the peripheral blood. The most pronounced was an increase of neutrophiles at the stage of tumor development, and their decline with tumour regression. The enlargement of the spleen and of the popliteal lymph nodes draining the tumour site, at the peak of tumor development on day 13 post MSV inoculation, involved at least a doubling of splenic weight, and a much greater weight increase for lymph nodes. This was a long-lasting, although declining event, extending beyond tumor regression.
Asunto(s)
Tejido Linfoide/patología , Virus del Sarcoma Murino de Moloney , Infecciones por Retroviridae/sangre , Sarcoma Experimental/sangre , Infecciones Tumorales por Virus/sangre , Animales , Recuento de Células Sanguíneas , Femenino , Tejido Linfoide/virología , Ratones , Ratones Endogámicos BALB C , Músculo Esquelético/patología , Infecciones por Retroviridae/patología , Infecciones por Retroviridae/virología , Sarcoma Experimental/patología , Sarcoma Experimental/virología , Infecciones Tumorales por Virus/patología , Infecciones Tumorales por Virus/virologíaRESUMEN
Although strong evidence is available suggesting that microenvironmental parameters play a role in lymphogenic or hematogenic metastasis, the underlying mechanisms are still unclear and further investigations of this topic are needed. For such a study however, an appropriate model of metastasis for in vivo analysis of this process would be required. An in vivo model of a solid tumor (rat DS sarcoma) has therefore been established to enable monitoring of the steps involved in tumor metastasis. Rat DS sarcoma cells were transfected with the pTracer-SV40 plasmid, containing the super-GFP and zeocin resistance genes. DS sarcoma cells showing high and stable expression of GFP (DSGFP cells) were selected by cell sorting and in vitro culturing with zeocin. To establish in vivo growth, DSGFP cells were subsequently injected intraperitoneally (i.p.) without additional selection by zeocin and GFP expression was monitored by flow cytometry. Using DSGFP ascites cells, solid tumors were implanted subcutaneously into the hind foot dorsum of rats. The expression of GFP was assayed by fluorescence microscopy. The detection of circulating DSGFP sarcoma cells in the blood was performed using the PCR technique. GFP expression in vitro was stable for more than 40 passages. Cell sorting, however, did not enable selection of a DSGFP cell population with a higher long-term stable GFP expression. After i.p. cell implantation, GFP expression in DSGFP ascites cells was maintained over at least 19 passages. Solid tumors implanted by injection of DSGFP ascites cells showed stable GFP expression. The growth rate of solid DSGFP sarcomas was slightly slower compared to that of non-transfected cell lines. The detection limit for circulating DS sarcoma cells in blood was 100 DSGFP cells/ml whole rat blood. Micrometastases in loco-regional lymph nodes, lung and liver were detectable by immunohistology and real-time PCR. This in vivo model showing stable expression of GFP could be useful for analyzing the mechanisms of metastasis, particularly where micrometastases or circulating tumor cells are to be identified.
Asunto(s)
Proteínas Fluorescentes Verdes/metabolismo , Metástasis de la Neoplasia/diagnóstico , Sarcoma Experimental/patología , Animales , ADN/análisis , ADN/genética , Proteínas Fluorescentes Verdes/genética , Inmunohistoquímica , Hígado/química , Hígado/patología , Pulmón/química , Pulmón/patología , Ganglios Linfáticos/química , Ganglios Linfáticos/patología , Microscopía de Contraste de Fase , Metástasis de la Neoplasia/genética , Reacción en Cadena de la Polimerasa , Ratas , Sarcoma Experimental/sangre , Sarcoma Experimental/genética , TransfecciónRESUMEN
Ganopoly is an aqueous polysaccharide fraction extracted from G. lucidum by patented biochemical technique and has been marketed as an over-the-counter product for chronic diseases including cancer and hepatopathy in many Asian countries. This study was undertaken to explore the anti-tumour effect and the underlying mechanisms of Ganopoly in mice and human tumor cell lines. The maximum tolerated dose (MTD) of Ganopoly in mice was estimated to be 100 mg/kg from a pilot study. Treatment of mice with oral Ganopoly for 10 days significantly reduced the tumour weight of sarcoma-180 in a dose-dependent manner, with inhibition rates of 32.3, 48.2 and 84.9% and growth delays of 1.5, 3.5, and 13.1 days at 20, 50, and 100 mg/kg, respectively. Incubation of Ganopoly at 0.05-1.0 mg/ml for 48 hours showed little or negligible cytotoxicity against human tumor CaSki, SiHa, Hep3B, HepG2, HCT116 HT29, and MCF7 cells in vitro. In contrast, 10 mg/ml of Ganopoly caused significant cytotoxicity in all tumour cells tested except MCF7, with marked apoptotic effect observed in CaSki, HepG2, and HCT116 cells, as indicated by nuclear staining and DNA fragmentation. In addition, Ganopoly enhanced concanavalin A-stimulated proliferation of murine splenocytes by 35.3% at 10 mg/ml, and stimulated the production of nitric oxide in thioglycollate-primed murine peritoneal macrophages in a concentration-dependent manner over 0.05-10 mg/ml. Addition of Ganopoly at 1 mg/ ml to murine peritoneal macrophages also potentiated lipopolysaccharide-induced nitric oxide production by 64.2%. Treatment of healthy mice or mice bearing sarsoma-180 with oral Ganopoly over 20-100 mg/kg for 7 day significantly increased the expression of both TNF-alpha and IFN-gamma (at both mRNA and protein levels) in splenocytes in a dose-dependent manner. Moreover, treatment of Ganopoly over 20-100 mg/kg significantly increased cytotoxic T lymphocyte cytotoxicity and NK activity in mice. The overall findings indicated that Ganopoly had antitumor activity with a broad spectrum of immuno-modulating activities and may represent a novel promising immunotherapeutic agent in cancer treatment.
Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Medicamentos Herbarios Chinos/farmacología , Polisacáridos/farmacología , Reishi/química , Sarcoma Experimental/tratamiento farmacológico , Animales , Antineoplásicos Fitogénicos/uso terapéutico , Apoptosis , Línea Celular Tumoral , Citocinas/biosíntesis , Evaluación Preclínica de Medicamentos , Medicamentos Herbarios Chinos/uso terapéutico , Humanos , Factores Inmunológicos/uso terapéutico , Interferón gamma/biosíntesis , Células Asesinas Naturales/inmunología , Macrófagos Peritoneales/efectos de los fármacos , Macrófagos Peritoneales/metabolismo , Masculino , Ratones , Óxido Nítrico/biosíntesis , Óxido Nítrico/sangre , Polisacáridos/aislamiento & purificación , Polisacáridos/uso terapéutico , Sarcoma Experimental/sangre , Sarcoma Experimental/patología , Bazo/efectos de los fármacos , Bazo/metabolismo , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Factor de Necrosis Tumoral alfa/biosíntesisRESUMEN
The experiments were made with 83 outbred male rats with transplanted sarcoma-45. The method of initiated chemiluminescence (CL) was used to measure the parameters of blood-serum lipid peroxidation in the animals. The index of free-radical blood-serum lipid peroxidation was shown to reflect in rats the tumor-body ratio. Initially, the kinetic parameters of induced CL were significantly increasing, which was accompanied by a minor remission of the tumor volume. The subsequent stages of tumor growth were associated with increasing, parameters in the studied enzymes' activity, which is apparently related with the expression of genes crucial for the body's antioxidant properties. This enables the tumor cells to escape the monitoring of non-specific cellular immunity with the result being an uncontrollable tumor-volume growth.
Asunto(s)
Biomarcadores de Tumor/sangre , Depuradores de Radicales Libres/sangre , Peróxidos Lipídicos/sangre , Sarcoma Experimental/sangre , Animales , Cinética , Oxidación-Reducción , RatasRESUMEN
Cartilage-derived retinoic acid-sensitive protein (CD-RAP) is a new protein that was isolated from bovine articular chondrocytes and human melanoma cell lines (melanoma inhibitory protein or MIA). In normal tissue its expression is limited to cartilage, and in morbid tissue to melanoma, chondrosarcoma, and breast cancer. Serum levels of CD-RAP/MIA correlate with the progression of malignant melanoma, but there have been no reports on chondrosarcoma. Here, it was first demonstrated by RT-PCR and immunohistological methods that CD-RAP was expressed in tissue from a Swarm rat chondrosarcoma that was used as an experimental model. The course following tumor transplantation and changes in serum CD-RAP after tumor excision were then observed to investigate whether serum CD-RAP could be used as a marker of tumor activity. Consequently, serum CD-RAP in control rats tended to decrease as the animal grew, whereas it rose in proportion to tumor proliferation in rats that had received a tumor graft. Serum CD-RAP levels dropped rapidly following excision of the tumor in a group of tumor-excised rats. In those rats which had a recurrence following excision of the tumor, serum CD-RAP rose prior to the appearance of the tumor. Serum CD-RAP thus sensitively reflected tumor onset and proliferation, so that it appeared to be an effective marker of tumor activity for Swarm rat chondrosarcoma.
Asunto(s)
Neoplasias Óseas/metabolismo , Condrosarcoma/metabolismo , Proteínas/análisis , Sarcoma Experimental/sangre , Animales , Neoplasias Óseas/patología , Neoplasias Óseas/cirugía , Condrosarcoma/patología , Condrosarcoma/cirugía , Regulación Neoplásica de la Expresión Génica , Inmunohistoquímica , Masculino , Recurrencia Local de Neoplasia , Trasplante de Neoplasias , Proteínas/genética , ARN Mensajero/metabolismo , ARN Neoplásico/análisis , Ratas , Ratas Sprague-Dawley , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Sarcoma Experimental/patología , Sarcoma Experimental/cirugía , Resultado del Tratamiento , Células Tumorales CultivadasRESUMEN
The effects of dose per fraction on the ability of amifostine exposure to elevate angiostatin levels in the serum of mice and to inhibit spontaneous metastases formation using the well-characterized murine Sa-NH sarcoma were investigated. Amifostine was administered intraperitoneally at doses of 50, 100, or 200 mg/kg every other day for 6 days to C3Hf/Kam mice until tumors reached an average size of 8 mm in diameter. Amifostine was again administered immediately following surgical removal of the tumor-bearing limbs by amputation, and then once more 2 days later. Nontumor-bearing control animals were treated using the same dosing and surgery schedules. The average number of pulmonary metastases per animal was determined for each experimental group. A significant reduction (P <.05) in the average number of pulmonary metastases was observed only in the group of animals exposed to a dose per fraction of 50 mg/kg. A dose of 100 mg/kg was less effective while 200 mg/kg had no effect on metastases formation in this study. The effects of amifostine exposure on serum levels of the angiogenesis inhibitor angiostatin were also determined using Western analysis. Correlating with the antimetastatic effect measured, exposure of animals to 50 mg/kg of amifostine resulted in a four-fold enhanced serum level of angiostatin above control levels. This phenomenon occurred in both tumor-bearing as well as nontumor-bearing animals. In contrast, a dose of 200-mg/kg amifostine administered intraperitoneally under these conditions had no measurable effect on angiostatin serum levels in this animal system. The enhanced ability of relatively low doses of amifostine to inhibit spontaneous metastases formation suggests that effective antimetastatic therapies with amifostine can be designed with minimal toxic side effects. While the dose responses for angiostatin production and metastases inhibition by amifostine are well correlated, the precise mechanism of action underlying these phenomena is unclear but is suggestive of a redox driven process(es).
Asunto(s)
Amifostina/farmacología , Antineoplásicos/farmacología , Citoprotección , Metástasis de la Neoplasia , Protectores contra Radiación/farmacología , Sarcoma Experimental/tratamiento farmacológico , Amifostina/administración & dosificación , Angiostatinas , Animales , Antineoplásicos/administración & dosificación , Ratones , Ratones Endogámicos C3H , Fragmentos de Péptidos/sangre , Plasminógeno , Protectores contra Radiación/administración & dosificación , Sarcoma Experimental/sangre , Sarcoma Experimental/patología , Sarcoma Experimental/cirugíaRESUMEN
We have reported that immunization of rat tumor-derived endothelial cells (TEC) isolated from KMT-17 solid tumors results in the generation of several monoclonal antibodies (MAbs). TES-23, one of these MAbs, recognizes a naturally occurring 80-kDa antigen expressed on endothelial cells of tumor blood vessels. To determine whether such MAbs can suppress solid tumor growth in vivo by impairment of endothelial cells in tumors following direct binding, we tested the biodistribution of (125)I-labeled TES-23 in rats bearing KMT-17 solid tumors. We also examined the effect of treatment using unconjugated TES-23 on tumor growth and histo-pathological changes in tumor tissues. Biodistribution studies showed localization of TES-23 into tumor tissues 60 min after intravenous injection. TES-23 suppressed significantly the growth of KMT-17 solid tumors following administration for 5 days. Histo-pathological examination showed that TES-23 caused degeneration, apoptosis and/or necrosis and denudation of endothelial cells in viable tumor areas following local aggregation and adhesion of lymphocytes, with subsequent intravascular thrombus formation by platelets and fibrin. Our results indicate that TES-23, which recognizes TEC, can target endothelial cells of solid tumor vasculature directly, resulting in growth suppression in vivo by reduction of blood flow due to intravascular thrombosis. Our results also suggest that targeting tumor vasculature is a potentially attractive approach for the treatment of solid tumors.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Endotelio Vascular/inmunología , Fibrosarcoma/terapia , Neovascularización Patológica/inmunología , Animales , Anticuerpos Monoclonales/farmacocinética , Recuento de Células Sanguíneas , Adhesión Celular , Agregación Celular , División Celular , Supervivencia Celular , Cisplatino/uso terapéutico , Endotelio Vascular/patología , Femenino , Fibrosarcoma/sangre , Fibrosarcoma/irrigación sanguínea , Fibrosarcoma/patología , Hematócrito , Hemoglobinas/análisis , Radioisótopos de Yodo/farmacocinética , Linfocitos/fisiología , Ratas , Ratas Endogámicas , Sarcoma Experimental/sangre , Sarcoma Experimental/irrigación sanguínea , Sarcoma Experimental/patología , Sarcoma Experimental/terapia , Distribución TisularRESUMEN
The aim of the investigation was to study the antitumor action of weak ultra low-frequency magnetic field (ULFMF) and application of a spectrum of dehydrogenases of peripheral blood lymphocytes as a sensitive indicator of such action in tumor S45-bearing rats. It was shown that application of weak ULFMF improves antitumor defenses and dehydrogenase activity tends to stay normal. The dehydrogenase activity of peripheral blood lymphocytes can be used to assess immune system tension and synchronization of resistance processes.
Asunto(s)
Linfocitos/enzimología , Oxidorreductasas/efectos de la radiación , Sarcoma Experimental/sangre , Sarcoma Experimental/radioterapia , Animales , Relación Dosis-Respuesta en la Radiación , Femenino , Linfocitos/efectos de la radiación , Dosificación Radioterapéutica , Ratas , Sarcoma Experimental/enzimología , Sarcoma Experimental/inmunologíaRESUMEN
PURPOSE: In a methodological study the applicability of hyperlactacidaemia in isolated hyperthermic perfusion of tumour-bearing rat limbs was investigated. METHODS: In 50 Sprague Dawley rats, DS-sarcoma growth was initiated on the right food dorsum by subcutaneous injection of 0.5 ml ascites cells. In the anaesthetized animals isolated limb perfusion was performed under steady state conditions for 60min using a miniature equipment. Thereafter tumour volume was measured daily. (a) Investigation of feasability: 40 rats were allocated to four groups. Group I: Normothermic perfusion at 38 degrees C, n = 10; Group II: Hyperthermic perfusion at 40-41 degrees C, n = 10; Group III: Normothermic perfusion at 38 degrees C and hyperlactacidaemia of 10 mmol/l, n = 10; Group IV: Hyperthermic perfusion at 40-41 degrees C and hyperlactacidaemia of 10 mmol/l, n = 10. (b) Investigation of survival and histological changes: In group V hyperthermic perfusion at 40-41 degrees C and hyperlactacidaemia of 10 mmol/l, n = 10 was performed. After the animals had died, hip disarticulation of the tumour-bearing limb was performed for histological examination. RESULTS: Normothermic and hyperthermic perfusion of tumour-bearing rat limbs using miniature equipment was feasible and tolerated by the animals. Regional hyperlactacidaemia of 10 mmol/l could be maintained throughout the perfusions. After combined treatment with hyperthermia and hyperlactacidaemia, tumour volume decreased and extensive tumour necrosis occurred, while in other animals aggressive tumour growth with bone infiltration could be observed. CONCLUSIONS: The present study demonstrates the applicability of hyperlactacidaemia in hyperthermic isolated limb perfusion in the rat and proved a tumour growth delay due to an induction of tumour necrosis thereafter. Further investigations in other tumour entities and experimental models are required to confirm this impressive therapeutic effect of hyperthermia in combination with hyperlactacidaemia.
Asunto(s)
Quimioterapia del Cáncer por Perfusión Regional , Hipertermia Inducida , Ácido Láctico/sangre , Sarcoma Experimental/terapia , Animales , Extremidades/patología , Estudios de Factibilidad , Femenino , Factores Inmunológicos , Ratas , Ratas Sprague-Dawley , Sarcoma Experimental/sangre , Sarcoma Experimental/patologíaRESUMEN
Cancer immunotherapy often aims at the reactivation and expansion of tumor-specific CTL. In an attempt to correlate in situ and/or systemic tumor-specific T cell expansion with tumor regression, we investigated the effects of adenovirus-mediated IL-12 or IFN-gamma gene transfer into established P815 murine tumors. While IFN-gamma was no more potent than the vector alone, IL-12 gene transfer promoted tumor eradication. Despite this antitumor effect, no significant cytolytic activity was detectable using classical cytotoxicity assays from in vitro restimulated splenocytes. Since intratumor gene delivery may induce a localized expansion of CTL, the presence of P815-specific CD8+ T cells in situ was assessed. Using the Immunoscope approach, we found a dramatic increase in clonotypic T cells at the tumor site following IL-12, but not IFN-gamma gene delivery. Antitumor CD8+ T cell frequencies were then re-evaluated using this molecular detection technique, which revealed a comparable expansion of specific T cells in the peripheral organs, most strikingly in the blood. These data show that local IL-12 gene transfer, in contrast to IFN-gamma, mediates a potent antitumor effect that correlates to clonal tumor-specific T cell expansions in situ and in the periphery.
Asunto(s)
Linfocitos T CD8-positivos/inmunología , Epítopos de Linfocito T/sangre , Terapia Genética , Interleucina-12/genética , Sarcoma de Mastocitos/terapia , Sarcoma Experimental/terapia , Subgrupos de Linfocitos T/inmunología , Adenoviridae/genética , Animales , Linfocitos T CD8-positivos/metabolismo , Movimiento Celular/genética , Movimiento Celular/inmunología , Citotoxicidad Inmunológica/genética , Femenino , Terapia Genética/métodos , Vectores Genéticos/administración & dosificación , Vectores Genéticos/uso terapéutico , Inyecciones Intravenosas , Interferón gamma/biosíntesis , Interleucina-12/metabolismo , Interleucina-12/uso terapéutico , Recuento de Linfocitos , Sarcoma de Mastocitos/sangre , Sarcoma de Mastocitos/genética , Sarcoma de Mastocitos/inmunología , Ratones , Ratones Endogámicos DBA , Recombinación Genética , Sarcoma Experimental/sangre , Sarcoma Experimental/genética , Sarcoma Experimental/inmunología , Subgrupos de Linfocitos T/metabolismo , Factores de TiempoRESUMEN
An experimental treatment with rose bengal showed that optimal effectiveness of photodynamic therapy of sarcoma M-1 was achieved 3-4 hr after intraperitoneal injection of 10 mg/kg body.
Asunto(s)
Antineoplásicos/farmacología , Fotoquimioterapia/métodos , Rosa Bengala/farmacología , Sarcoma Experimental/tratamiento farmacológico , Animales , Inyecciones , Cavidad Peritoneal , Ratas , Sarcoma Experimental/sangreRESUMEN
Although reduced biological activity of the obese gene product, leptin, has been associated with obesity, little information is available concerning leptin alterations during anorexia. Therefore, we measured circulating leptin concentrations and hypothalamic leptin binding in anorectic tumor-bearing and pair-fed control rats. Plasma concentrations of leptin decreased in tumor-bearing rats early in the course of tumor growth, and fell to nearly non-detectable levels during severe anorexia. The pair-fed control rats that ate the same amount of food as did the anorectic tumor-bearing rats exhibited a 50% decrease in plasma leptin concentration. Concentrations of free fatty acids were elevated in both tumor-bearing and pair-fed groups, while circulating levels of triglycerides were increased only in anorectic tumor-bearing rats. Leptin receptor density was doubled in the hypothalamus of tumor bearing rats, while binding affinity was decreased by 50%. These results suggest that peripheral leptin production is down-regulated, perhaps due to increased lipolysis in tumor-bearing rats. It appears that hypothalamic leptin systems up-regulate receptor numbers in response to decreased blood leptin level, however, the decrease in binding affinity may compensate for these alterations. Therefore, the influence of leptin on hypothalamic neuropeptide Y feeding systems may be minimal in anorectic tumor-bearing rats.
Asunto(s)
Anorexia/metabolismo , Proteínas Portadoras/metabolismo , Hipotálamo/metabolismo , Proteínas/metabolismo , Receptores de Superficie Celular , Sarcoma Experimental/metabolismo , Animales , Anorexia/sangre , Peso Corporal , Ingestión de Alimentos/fisiología , Ayuno , Ácidos Grasos no Esterificados/sangre , Hipotálamo/fisiología , Leptina , Masculino , Obesidad/metabolismo , Unión Proteica , Ratas , Ratas Endogámicas F344 , Receptores de Leptina , Sarcoma Experimental/sangreRESUMEN
The radiosensitivity of solid tumours in anaemic rats treated with recombinant human erythropoietin (rhEPO, epoetin beta) was studied. Anaemia was induced by a single dose of carboplatin (45 mg kg(-1) i.v.), resulting in a reduction in the haemoglobin concentration by 30%. In a second group, the development of anaemia was prevented by rhEPO (1000 IU kg(-1)) administered s.c. three times per week starting 6 days before the carboplatin application. Three days after carboplatin treatment, DS-sarcomas were implanted subcutaneously onto the hind foot dorsum. Neither carboplatin nor rhEPO treatment influenced tumour growth rate. Five days after implantation, tumours were irradiated with a single non-curative dose (10 Gy), resulting in a growth delay with a subsequent regrowth of the tumours. In the rhEPO-treated group, the growth delay lasted significantly longer (9.5 days vs. 4.5 days) and the regrowth was slower (6.0 days vs. 4.1 days) compared with the anaemic group. These data suggest that the correction of chemotherapy-induced anaemia by rhEPO (epoetin beta) treatment increases tumour radiosensitivity, presumably as a result of an improved oxygen supply to tumour tissue.
Asunto(s)
Anemia/prevención & control , Eritropoyetina/uso terapéutico , Sarcoma Experimental/radioterapia , Anemia/sangre , Anemia/inducido químicamente , Anemia/tratamiento farmacológico , Animales , Antineoplásicos/efectos adversos , Carboplatino/efectos adversos , Hemoglobinas/efectos de los fármacos , Humanos , Masculino , Trasplante de Neoplasias , Tolerancia a Radiación , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes , Sarcoma Experimental/sangreRESUMEN
The effect of localized hypothermia on microcirculatory and metabolic parameters in s.c. DS sarcomas on the hind foot dorsum of Sprague-Dawley rats was investigated. Tumours were cooled by superfusion of the tumour surface with cooled saline solution to 25 degrees C or 15 degrees C. Control tumours remained at 35 degrees C. These temperatures were maintained for 30 min. In tumour oxygenation measurements, hypothermia at 25 degrees C and 15 degrees C caused progressive decreases in the size of the fraction of pO2 measurements between 0 and 2.5 mmHg together with a reduction in pO2 variability. No significant changes in median or mean pO2 or in the fraction of pO2 measurements between 0 and 5 mmHg, and 0 and 10 mmHg were observed. Using laser Doppler flowmetry, red blood cell flux was found to decrease significantly upon 25 degrees C or 15 degrees C hypothermia treatment to 67% and 37% of starting values respectively, whereas no significant changes were seen in control tumours over the whole observation period. Viscosity was measured in blood and plasma samples over a range of temperatures and was found to increase with decreasing temperature. Assessment of tumour glucose levels showed an increased concentration of glucose following 15 degrees C hypothermia, an observation consistent with a 'slowing down' of glycolysis. No changes in lactate or adenylate phosphate levels were observed. As a way of improving tumour oxygenation, localized hypothermia may therefore be a useful means of radiosensitization.
Asunto(s)
Hipotermia Inducida , Consumo de Oxígeno , Sarcoma Experimental , Neoplasias Cutáneas , Animales , Viscosidad Sanguínea , Flujometría por Láser-Doppler , Masculino , Microcirculación , Ratas , Ratas Sprague-Dawley , Sarcoma Experimental/sangre , Sarcoma Experimental/irrigación sanguínea , Sarcoma Experimental/metabolismo , Sarcoma Experimental/terapia , Neoplasias Cutáneas/sangre , Neoplasias Cutáneas/irrigación sanguínea , Neoplasias Cutáneas/metabolismo , Neoplasias Cutáneas/terapiaRESUMEN
PURPOSE: To measure the effects of breathing high-oxygen-content gases, with a CO2 fraction of between 0 and 10%, on tumour radiosensitivity, blood flow and oxygenation. METHODS AND MATERIALS: The murine sarcoma F was used, implanted subcutaneously (s.c.) in syngeneic CBA mice. We assessed the induced changes in tumour microregional blood flow and oxygenation using laser Doppler flowmetry, and pO2 histography, respectively. Radiation response was determined using an in vivo-in vitro clonogenic assay 18-20 h post treatment. RESULTS: The results show that the level of radiosensitization achieved is dependent on both the CO2 content of the inspired gas and the duration of gas breathing. No radiosensitization was evident following inhalation of 90% O2 + 10% CO2. All other gases elicited radiosensitization; however, that achieved with 100% O2 disappeared at the extended preirradiation breathing time of 45 min. At this time, radiosensitization was maintained for gases containing 1%, 2.5%, or 5% CO2. Changes in oxygenation, as measured by PO2 electrodes, did indicate improved oxygenation status during inhalation of the gases. However, the time-course and extent of the changes did not mirror accurately the changes in radiosensitization. All the gases with a CO2 content of 2.5% or greater induced a 10-20% reduction in microregional blood flow, with no change evident following inhalation of 100% O2 or 99% O2 + 1% CO2. CONCLUSIONS: The data imply that the decreased radiosensitization seen at extended breathing times of oxygen is unrelated to blood flow changes. The fact that radiosensitization is seen with extended breathing times of gases containing 2.5% and 5% CO2, despite blood flow decreases, is indicative of other overriding physiological changes, perhaps related to oxygen utilisation. The studies overall indicate that, at least in the tumour investigated, radiosensitization is not affected if the CO2 content of the inspired gas is reduced from 5% to 2.5%, or even 1%. Further evaluation of the radiosensitizing effects of such gas mixtures is now warranted. In addition, comparison with recent studies of other tumour types, where carbogen has been shown to improve tumour blood flow, suggests that this may be a tumour-specific phenomenon. Based on these data, further effort is required to elucidate the physiological mechanisms that determine these blood flow changes.
Asunto(s)
Dióxido de Carbono/administración & dosificación , Oxígeno/administración & dosificación , Oxígeno/sangre , Fármacos Sensibilizantes a Radiaciones/administración & dosificación , Sarcoma Experimental/radioterapia , Administración por Inhalación , Animales , Hipoxia de la Célula , Ratones , Ratones Endogámicos CBA , Microcirculación , Trasplante de Neoplasias , Presión Parcial , Tolerancia a Radiación , Sarcoma Experimental/sangreRESUMEN
HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, the rate limiting enzyme in cholesterol synthesis, catalyses mevalonate production and, hence, influence the synthesis of isoprenoid metabolites. It has already been demonstrated that products of the mevalonate pathway play an important role in the progress of the cell cycle and cell survival. Lovastatin (LOV) competitively inhibits HMG-CoA reductase, blocking the synthesis of mevalonic acid and the generation of non-sterol isoprenoids, such as farnesyl residues. The posttranslational farnesylation of p21ras protein is essential for its binding to the membrane and, therefore, for its transforming activity. Considering that p21ras protein was reported to have a significant rol in metastatic behavior of tumor cells, we decided to study LOV as an antimetastatic agent on a rat fibrosarcoma. We demonstrated that a short treatment with LOV diminished primary tumor growth and the number and size of lung experimental metastasis.